^
Association details:
| Biomarker: | SMARCB1 mutation |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Tazverik (tazemetostat) (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Published date:
10/06/2020
Excerpt:
Patients eligible for the epithelioid sarcoma cohort (cohort 5) were aged 16 years or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma; documented loss of INI1 expression by immunohistochemical analysis or biallelic SMARCB1 (the gene that encodes INI1) alterations, or both;...16 (26% [95% CI 16–39]) patients had disease control at 32 weeks. Median time to response was 3·9 months (IQR 1·9–7·4). Median progression-free survival was 5·5 months (95% CI 3·4–5·9), and median overall survival was 19·0 months (11·0–not estimable).
DOI:
https://doi.org/10.1016/S1470-2045(20)30451-4
Trial ID:
